Clofibrate, fibrinolysis, and platelet stickiness.
نویسندگان
چکیده
منابع مشابه
Platelet stickiness in multiple sclerosis.
Nathanson and Savitsky (1952) were the first to study platelet adhesiveness in patients suffering from multiple sclerosis (60 in all). Increased adhesiveness was found in the groups of patients with acute exacerbations or a fluctuating course: the average 'adhesive index' for the stationary group was within the normal range. More recently two preliminary communications were published on the sam...
متن کاملClofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia.
Platelet function was evaluated in 29 patients with familial hyperbetalipoproteinemia; 17 were untreated and 12 were receiving clofibrate (Atromid-S). In comparison with 26 normal subjects, the untreated patients aggregated in response to 1/3 the concentration of adenosine diphosphate (ADP), '/25 the concentration of epinephrine, and '/4 the concentration of collagen. Treatment with clofibrate,...
متن کاملPlatelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation.
BACKGROUND Although plasminogen activator therapy has been shown to reduce mortality in patients with severe myocardial infarction, several problems fuel the search for more potent and specific thrombolytic agents. METHODS AND RESULTS To explore the effect of plasminogen activator targeting to platelets, we covalently linked urokinase that had been modified with N-succinimidyl-3-(2-pyridyldit...
متن کاملInhibition of in vitro platelet aggregation and release and fibrinolysis.
Inhibition of in vitro platelet aggregation and release of contents of platelet granules is necessary in order to assess accurately platelet activation in vivo. This can be accomplished by using a variety of inhibitors added to blood collection containers. An additive mixture of citrate, theophylline, adenosine, and dipyridamole (CTAD) provides a practical alternative to a mixture of acid citra...
متن کاملEffects of clofibrate with androsterone (atromid) and without androsterone (atromid-S) on blood platelets and lipids in ischaemic heart disease.
A mixture of androsterone and clofibrate (atromid) lowers the blood cholesterol and triglycerides (Oliver, 1962). Clofibrate without androsterone (atromid-S) appears to have the same effect on the serum lipids (Oliver, 1963; Hellman et al., 1963). Atromid lowers platelet stickiness (Carson et al., 1963a, b) which is increased in patients with ischamic heart disease (McDonald and Edgill, 1957); ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1970
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.4.5727.114-a